| UHC UMR Medical and Drug | Elevidys® (Delandistrogene Moxeparvovec-Rokl) – Commercial Medical Benefit Drug Policy | 2026-03-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Site of Care | 2026-03-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Tocilizumab (Actemra) and Tocilizumab Biosimilars | 2026-03-01 |
| BCBS Highmark NY and West NY | Tocilizumab (Actemra) and Tocilizumab Biosimilars | 2026-03-01 |
| BCBS Highmark Delaware | Tocilizumab (Actemra) and Tocilizumab Biosimilars | 2026-03-01 |
| BCBS Highmark West Virginia | Tocilizumab (Actemra) and Tocilizumab Biosimilars | 2026-03-01 |
| BCBS California | Renal Denervation for Uncontrolled Hypertension | 2026-03-01 |
| BCBS California | Tonic Motor Activation for Restless Legs Syndrome | 2026-03-01 |
| UHC UMR Medical and Drug | Tocilizumab (Actemra®, Tofidence®, & Tyenne®) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-03-01 |
| UHC Surest Medical and Drug | Tocilizumab (Actemra®, Tofidence®, & Tyenne®) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-03-01 |